Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2024 | Osteoarthrosis | Research

Calycosin ameliorates osteoarthritis by regulating the imbalance between chondrocyte synthesis and catabolism

Authors: Hong Su, Qiuju Yan, Wei Du, En Hu, Zhaoyu Yang, Wei Zhang, Yusheng Li, Tao Tang, Shushan Zhao, Yang Wang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2024

Abstract

Osteoarthritis (OA) is a severe chronic inflammatory disease. As the main active component of Astragalus mongholicus Bunge, a classic traditional ethnic herb, calycosin exhibits anti-inflammatory action and its mechanism of exact targets for OA have yet to be determined. In this study, we established an anterior cruciate ligament transection (ACLT) mouse model. Mice were randomized to sham, OA, and calycosin groups. Cartilage synthesis markers type II collagen (Col-2) and SRY-Box Transcription Factor 9 (Sox-9) increased significantly after calycosin gavage. While cartilage matrix degradation index cyclooxygenase-2 (COX-2), phosphor-epidermal growth factor receptor (p-EGFR), and matrix metalloproteinase-9 (MMP9) expression were decreased. With the help of network pharmacology and molecular docking, these results were confirmed in chondrocyte ADTC5 cells. Our results indicated that the calycosin treatment significantly improved cartilage damage, this was probably attributed to reversing the imbalance between chondrocyte synthesis and catabolism.

Available only for authorised users

Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;13(2):16072. https://doi.org/10.1038/nrdp.2016.72.CrossRef

Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–223. https://doi.org/10.1016/S0140-6736(12)61689-4.CrossRefPubMed

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9.CrossRef

Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. Nat Rev Rheumatol. 2015;11(1):35–44. https://doi.org/10.1038/nrrheum.2014.162.CrossRefPubMed

Bridgewater LC, Lefebvre V, de Crombrugghe B. Chondrocyte-specific enhancer elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer. J Biol Chem. 1998;273(24):14998–5006. https://doi.org/10.1074/jbc.273.24.14998.CrossRefPubMed

de Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W. Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol. 2000;19(5):389–94. https://doi.org/10.1016/s0945-053x(00)00094-9.CrossRefPubMed

Husa M, Liu-Bryan R, Terkeltaub R. Shifting HIFs in osteoarthritis. Nat Med. 2010;16(6):641–4. https://doi.org/10.1038/nm0610-641.CrossRefPubMedPubMedCentral

Lefebvre V, Smits P. Transcriptional control of chondrocyte fate and differentiation. Birth Defects Res C Embryo Today. 2005;75(3):200–12. https://doi.org/10.1002/bdrc.20048.CrossRefPubMed

Geng Y, Blanco FJ, Cornelisson M, Lotz M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J Immunol. 1995;155(2):796–801.CrossRefPubMed

10.

Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: Hopes and disappointments. Nat Rev Rheumatol. 2013;9(7):400–10. https://doi.org/10.1038/nrrheum.2013.44.CrossRefPubMed

11.

Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflamm- atory disease: Potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001;44(6):1237–47. https://doi.org/10.1002/1529-0131(200106)44:6>1237::AID-ART214>3.0.CO;2-F.CrossRefPubMed

12.

Pest MA, Russell BA, Zhang Y-W, Jeong J-W, Beier F. Disturbed cartilage and joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a mouse model of joint dysfunction. Arthritis Rheumatol. 2014;66(10):2816–27. https://doi.org/10.1002/art.38758.CrossRefPubMedPubMedCentral

13.

Staal B, Williams BO, Beier F, VandeWoude GF, Zhang Y-W. Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation. Proc Natl Acad Sci U S A. 2014;111(7):2590–5. https://doi.org/10.1073/pnas.1400744111.CrossRefPubMedPubMedCentral

14.

Appleton CTG, Usmani SE, Bernier SM, Aigner T, Beier F. Transforming growth factor alpha suppression of articular chondrocyte phenotype and Sox9 expression in a rat model of osteoarthritis. Arthritis Rheum. 2007;56(11):3693–705. https://doi.org/10.1002/art.22968.CrossRefPubMed

15.

Long DL, Ulici V, Chubinskaya S, Loeser RF. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is increased in osteoarthritis and regulates chondrocyte catabolic and anabolic activities. Osteoarthritis Cartilage. 2015;23(9):1523–31. https://doi.org/10.1016/j.joca.2015.04.019.CrossRefPubMedPubMedCentral

16.

Zengini E, Hatzikotoulas K, Tachmazidou I, et al. Genome-wide analyses using UK Biobank data provide insights into the genetic architecture of osteoarthritis. Nat Genet. 2018;50(4):549–58. https://doi.org/10.1038/s41588-018-0079-y.CrossRefPubMedPubMedCentral

17.

Zhang X, Siclari VA, Lan S, Zhu J, Koyama E, Dupuis HL, Enomoto-Iwamoto M, Beier F, Qin L. The critical role of the epidermal growth factor receptor in endochondral ossification. J Bone Miner Res. 2011;26(11):2622–33. https://doi.org/10.1002/jbmr.502.CrossRefPubMed

18.

Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum. 2008;38(3):165–87. https://doi.org/10.1016/j.semarthrit.2007.10.004.CrossRefPubMed

19.

Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–55. https://doi.org/10.1001/jama.284.10.1247.CrossRefPubMed

20.

Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283(3):1069–75.PubMed

21.

Lader E. ACP Journal Club. Review: NSAIDs increase GI and CV events; coxibs increase mortality. Ann Intern Med. 2013;159(8):JC12. https://doi.org/10.7326/0003-4819-159-8-201310150-02012.CrossRefPubMed

22.

Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47(3):550–7. https://doi.org/10.1021/jm030912m.CrossRefPubMed

23.

Durazzo A, Nazhand A, Lucarini M, et al. Astragalus (Astragalus membranaceus Bunge): botanical, geographical, and historical aspects to pharmaceutical components and beneficial role. Rend Fis Acc Lincei. 2021;32:625–42. https://doi.org/10.1007/s12210-021-01003-2.CrossRef

24.

Shahrajabian MH, Sun W, Cheng Q. A review of Astragalus species as foodstuffs, dietary supplements, a Traditional Chinese Medicine and a part of modern pharmaceutical science. Appl Ecol Environ Res. 2019.17(6):13371-82. https://doi.org/10.15666/aeer/1706_1337113382.

25.

Durazzo A, Nazhand A, Lucarini M, et al. Astragalus (Astragalus membranaceus Bunge): botanical, geographical, and historical aspects to pharmaceutical components and beneficial role. Rend Fis Acc Lincei. 2021;2021(32):625–42. https://doi.org/10.1007/s12210-021-01003-2.CrossRef

26.

Deng M, Chen H, Long J, Song J, Xie L, Li X. Calycosin: a Review of its Pharmacological Effects and Application Prospects. Expert Rev Anti Infect Ther. 2021;19(7):911–25. https://doi.org/10.1080/14787210.2021.1863145.CrossRefPubMed

27.

Dong L, Yin L, Chen R, Zhang Y, Hua S, Quan H, Fu X. Anti-inflammatory effect of Calycosin glycoside on lipopolysaccharide-induced inflammatory responses in RAW 264.7 cells. Gene. 2018;30(675):94–101. https://doi.org/10.1016/j.gene.2018.06.057.CrossRef

28.

Ting Hu, Liu Qi-Mei, He Xiao-Wei, Huang Fei, Zhang Ming-Wei, Jiang Jian-Guo. Identification of bioactives from Astragalus chinensis L.f. and their antioxidant, anti-inflammatory and anti-proliferative effects. J Food Sci Technol. 2017;54(13):4315–23. https://doi.org/10.1007/s13197-017-2902-3. Epub 2017 Oct 31.CrossRef

29.

Elsherbiny NM, Said E, Atef H, Zaitone SA. Renoprotective effect of calycosin in high fat diet-fed/STZ injected rats: Effect on IL-33/ST2 signaling, oxidative stress and fibrosis suppression. Chem Biol Interact. 2020;5(315):108897. https://doi.org/10.1016/j.cbi.2019.108897.CrossRef

30.

Fang Y, Xue Z, Zhao L, Yang X, Yang Y, Zhou X, Feng S, Chen K. Calycosin stimulates the osteogenic differentiation of rat calvarial osteoblasts by activating the IGF1R/PI3K/Akt signaling pathway. Cell Biol Int. 2019;43(3):323–32. https://doi.org/10.1002/cbin.11102.CrossRefPubMed

31.

Wang F, Qian H, Kong L, et al. Accelerated Bone Regeneration by Astragaloside IV through Stimulating the Coupling of Osteogenesis and Angiogenesis. Int J Biol Sci. 2021;17(7):1821–36. https://doi.org/10.7150/ijbs.57681.CrossRefPubMedPubMedCentral

32.

Guo X, Pan X, Wu J, Li Y, Nie N. Calycosin prevents IL-1beta-induced articular chondrocyte damage in osteoarthritis through regulating the PI3K/AKT/FoxO1 pathway. In Vitro Cell Dev Biol Anim. 2022;58(6):491–502. https://doi.org/10.1007/s11626-022-00694-7. Epub 2022 Jun 15.CrossRefPubMed

33.

Quan GH, Wang H, Cao J, et al. Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-kappaB. Int J Mol Sci. 2015;16(12):29496–507. https://doi.org/10.3390/ijms161226179.CrossRefPubMedPubMedCentral

34.

Shi X, Jie L, Wu P, Zhang N, Mao J, Wang P, et al. Calycosin mitigates chondrocyte inflammation and apoptosis by inhibiting the PI3K/AKT and NF-κB pathways. J Ethnopharmacol. 2022;28(297):115536. https://doi.org/10.1016/j.jep.2022.115536.CrossRef

35.

Lee W-Y, Chen H-Y, Chen K-C, Chen CY-C. Treatment of rheumatoid arthritis with traditional chinese medicine. Biomed Res Int. 2014;2014(2014): 528018. https://doi.org/10.1155/2014/528018.CrossRefPubMedPubMedCentral

36.

Tian J, Wang Y, Zhang X, Ren Q, Li R, Huang Y, Lu H, Chen J. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7–7-GPR30 Signaling. J Exp Clin Cancer Res. 2017;36(1):153. https://doi.org/10.1186/s13046-017-0625-y.CrossRefPubMedPubMedCentral

37.

Choi SI, Heo TR, Min BH, Cui JH, Choi BH, Park SR. Alleviation of osteoarthritis by calycosin-7-O-beta-D-glucopyranoside (CG) isolated from Astragali radix (AR) in rabbit osteoarthritis (OA) model. Osteoarthritis Cartilage. 2007;15(9):1086–92. https://doi.org/10.1016/j.joca.2007.02.015. Epub 2007 Apr 3.CrossRefPubMed

38.

Li X, Wei S, Niu S, et al. Network pharmacology prediction and molecular docking-based strategy to explore the potential mechanism of Huanglian Jiedu Decoction against sepsis. Comput Biol Med. 2022;144:105389. https://doi.org/10.1016/j.compbiomed.2022.105389.CrossRefPubMed

39.

Yuan C, Wang MH, Wang F, et al. Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer. Life Sci. 2021;1(270):119105. https://doi.org/10.1016/j.lfs.2021.119105.CrossRef

40.

Wang X, Wang ZY, Zheng JH, Li S. TCM network pharmacology: A new trend towards combining computational, experimental and clinical approaches. Chin J Nat Med. 2021;19(1):1–11. https://doi.org/10.1016/S1875-5364(21)60001-8.CrossRefPubMed

41.

Behzadi P, Ranjbar R. DNA microarray technology and bioinformatic web services. cta Microbiologica et Immunologica Hungarica. 2019;66(1):19–30. https://doi.org/10.1556/030.65.2018.028.CrossRef

42.

Behzadi P, Gajdács M. Writing a strong scientific paper in medicine and the biomedical sciences: a checklist and recommendations for early career researchers. Biol Futur. 2021;72(4):395–407. https://doi.org/10.1007/s42977-021-00095-z. Epub 2021 Jul 28.CrossRefPubMed

43.

Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197–206. https://doi.org/10.1038/nbt1284.CrossRefPubMed

44.

Tao W, Xu X, Wang X, et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol. 2013;145(1):1–10. https://doi.org/10.1016/j.jep.2012.09.051.CrossRefPubMed

45.

Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: A web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42(Web Server issue):W32-8. https://doi.org/10.1093/nar/gku293.CrossRefPubMedPubMedCentral

46.

Kuhn M, Szklarczyk D, Pletscher-Frankild S, Blicher TH, von Mering C, Jensen LJ, Bork P. STITCH 4: Integration of protein-chemical interactions with user data. Nucleic Acids Res. 2014;42(Database issue):D401-7. https://doi.org/10.1093/nar/gkt1207.CrossRefPubMed

47.

Ru J, Li P, Wang J, et al. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;16(6):13. https://doi.org/10.1186/1758-2946-6-13.CrossRef

48.

Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, Qiu Y, Chen Y. Therapeutic target database update 2022: Facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 2022;50(D1):D1398–407. https://doi.org/10.1093/nar/gkab953.CrossRefPubMed

49.

Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–82. https://doi.org/10.1093/nar/gkx1037.CrossRefPubMed

50.

Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res, 2015;43(Database issue):D789-98. https://doi.org/10.1093/nar/gku1205

51.

Safran Marilyn, Dalah Irina, Alexander Justin. GeneCards Version 3: The human gene integrator. Database (Oxford). 2010;2010:baq020. https://doi.org/10.1093/database/baq020.CrossRefPubMed

52.

Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13. https://doi.org/10.1093/nar/gky1131.CrossRefPubMed

53.

Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. https://doi.org/10.1093/nar/gkn923.CrossRefPubMed

54.

Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–61. https://doi.org/10.1093/nar/gkw1092.CrossRefPubMed

55.

UniProt Consortium. UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49(D1):D480–9. https://doi.org/10.1093/nar/gkaa1100.CrossRef

56.

Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235–42. https://doi.org/10.1093/nar/28.1.235.CrossRefPubMedPubMedCentral

57.

Behzadi P, Gajdács M. Worldwide Protein Data Bank (wwPDB): A virtual treasure for research in biotechnology. Eur J Microbiol Immunol (Bp). 2021;11(4):77–86. https://doi.org/10.1556/1886.2021.00020.CrossRefPubMed

58.

Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61. https://doi.org/10.1002/jcc.21334.CrossRefPubMedPubMedCentral

59.

Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24(5):417–22. https://doi.org/10.1007/s10822-010-9352-6.CrossRefPubMedPubMedCentral

60.

Ansari MA, Thiruvengadam M, Farooqui Z, et al. Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer. Semin Cancer Biol. 2021;69:109–28. https://doi.org/10.1016/j.semcancer.2019.12.022.CrossRefPubMed

61.

Kamekura S, Hoshi K, Shimoaka T, et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage. 2005;13(7):632–41. https://doi.org/10.1016/j.joca.2005.03.004.CrossRefPubMed

62.

Chen C, Cui J, Ji X, Yao L. Neuroprotective functions of calycosin against intracerebral hemorrhage-induced oxidative stress and neuroinflammation. Future Med Chem. 2020;12(7):583–92. https://doi.org/10.4155/fmc-2019-0311.CrossRefPubMed

63.

Pritzker KPH, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, Salter D, van den Berg WB. Osteoarthritis cartilage histopathology: Grading and staging. Osteoarthritis Cartilage. 2006;14(1):13–29. https://doi.org/10.1016/j.joca.2005.07.014.CrossRefPubMed

64.

Xue S, Zhou X, Sang W, et al. 2021 Cartilage-targeting peptide-modified dual-drug delivery nanoplatform with NIR laser response for osteoarthritis therapy. Bioact Mater. 2021;6(8):2372–89. https://doi.org/10.1016/j.bioactmat.2021.01.017.CrossRefPubMedPubMedCentral

65.

Bertrand J, Cromme C, Umlauf D, Frank S, Pap T. Molecular mechanisms of cartilage remodelling in osteoarthritis. Int J Biochem Cell Biol. 2010;42(10):1594–601. https://doi.org/10.1016/j.biocel.2010.06.022.CrossRefPubMed

66.

Mitchell PG, Magna HA, Reeves LM, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest. 1996;97(3):761–8. https://doi.org/10.1172/JCI118475.CrossRefPubMedPubMedCentral

67.

Mix KS, Sporn MB, Brinckerhoff CE, Eyre D, Schurman DJ. Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis. Clin Orthop Relat Res, 2004;(427 Suppl):S129–37. https://doi.org/10.1097/01.blo.0000144483.62033.8b

68.

Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221–33. https://doi.org/10.1038/nrm2125.CrossRefPubMedPubMedCentral

69.

Jia H, Ma X, Tong W, et al. EGFR signaling is critical for maintaining the superficial layer of articular cartilage and preventing osteoarthritis initiation. Proc Natl Acad Sci U S A. 2016;113(50):14360–5. https://doi.org/10.1073/pnas.1608938113.CrossRefPubMedPubMedCentral

70.

Sun H, Wu Y, Pan Z, et al. Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment. EBioMedicine. 2018;32:223–33. https://doi.org/10.1016/j.ebiom.2018.06.002.CrossRefPubMedPubMedCentral

71.

Nong Y, Liang Y, Liang X, Li Y, Yang B. Pharmacological targets and mechanisms of calycosin against meningitis. Aging (Albany NY). 2020;12(19):19468–92. https://doi.org/10.18632/aging.103886.CrossRefPubMed

72.

Xu H, Qin J, Qin L, Guo C, Yang B. Bioinformatics and In Silico Findings Uncover Bio-Targets of Calycosin Against Heart Failure and Diabetes Mellitus. Front Endocrinol (Lausanne). 2022;8(13):790619. https://doi.org/10.3389/fendo.2022.790619.CrossRef

73.

Wegiel B, Persson JL. Effect of a novel botanical agent Drynol Cibotin on human osteoblast cells and implications for osteoporosis: Promotion of cell growth, calcium uptake and collagen production. Phytother Res. 2010;24(Suppl 2):S139-47. https://doi.org/10.1002/ptr.3026.CrossRefPubMed

74.

Xie Q-F, Xie J-H, Dong TTX, et al. Effect of a derived herbal recipe from an ancient Chinese formula, Danggui Buxue Tang, on ovariectomized rats. J Ethnopharmacol. 2012;144(3):567–75. https://doi.org/10.1016/j.jep.2012.09.041.CrossRefPubMed

75.

MacDonald IJ, Liu S-C, Su CM, Wang YH, Tsai CH, Tang CH. Implications of Angiogenesis Involvement in Arthritis. Int J Mol Sci. 2018;19(7):2012. https://doi.org/10.3390/ijms19072012.CrossRefPubMedPubMedCentral

76.

Liu Y, Zeng Y, Si HB, Tang L, Xie HQ, Shen B. Exosomes derived from human urine-derived stem cells overexpressing miR-140–5p Alleviate Knee Osteoarthritis Through Downregulation of VEGFA in a Rat Mode. Am J Sports Med. 2022;50(4):1088–105. https://doi.org/10.1177/03635465221073991.CrossRefPubMed

77.

Spector TD, MacGregor AJ. Risk factors for osteoarthritis: Genetics. Osteoarthritis Cartilage. 2004;12 Suppl A:S39-44. https://doi.org/10.1016/j.joca.2003.09.005.CrossRefPubMed

78.

Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13(9):769–81. https://doi.org/10.1016/j.joca.2005.04.014.CrossRefPubMed

79.

Steinberg J, Southam L, Roumeliotis TI, et al. A molecular quantitative trait locus map for osteoarthritis. Nat Commun. 2021;12(1):1309. https://doi.org/10.1038/s41467-021-21593-7.CrossRefPubMedPubMedCentral

80.

Cassidy, A., Albertazzi, P. and Lise Nielsen. et al.. Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc, 2006;65(1):76–92. doi: https://doi.org/10.1079/pns2005476

81.

Nie Q, Xing M, Hu J, Hu X, Nie S, Xie M. Metabolism and health effects of phyto-estrogens. Crit Rev Food Sci Nutr. 2017;57(11):2432–54. https://doi.org/10.1080/10408398.2015.1077194.CrossRefPubMed

82.

Huang JG, Xia C, Zheng XP, Yi TT, Wang XY, Song G, Zhang B. 17β-Estradiol promotes cell proliferation in rat osteoarthritis model chondrocytes via PI3K/Akt pathway. Cell Mol Biol Lett. 2011;16(4):564–75. https://doi.org/10.2478/s11658-011-0023-y.CrossRefPubMedPubMedCentral

83.

Akhtar N, Khan NM, Ashruf OS, Haqqi TM. Inhibition of cartilage degradation and suppression of PGE2 and MMPs expression by pomegranate fruit extract in a model of posttraumatic osteoarthritis. Nutrition. 2017;33:1–13. https://doi.org/10.1016/j.nut.2016.08.004.CrossRefPubMed

84.

Lee SA, Moon S-M, Han SH, Hwang EJ, Park B-R, Kim J-S, Kim DK, Kim CS. Chondroprotective effects of aqueous extract of Anthriscus sylvestris leaves on osteoarthritis in vitro and in vivo through MAPKs and NF-κB signaling inhibition. Biomed Pharmacother. 2018;103:1202–11. https://doi.org/10.1016/j.biopha.2018.04.183.CrossRefPubMed

85.

Shi X, Jie L, Wu P, et al. Calycosin mitigates chondrocyte inflammation and apoptosis by inhibiting the PI3K/AKT and NF-kappaB pathways. J Ethnopharmacol. 2022;28(297):115536. https://doi.org/10.1016/j.jep.2022.115536.CrossRef

Title: Calycosin ameliorates osteoarthritis by regulating the imbalance between chondrocyte synthesis and catabolism
Authors: Hong Su
Qiuju Yan
Wei Du
En Hu
Zhaoyu Yang
Wei Zhang
Yusheng Li
Tao Tang
Shushan Zhao
Yang Wang
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Osteoarthrosis
Osteoarthrosis
Published in: BMC Complementary Medicine and Therapies / Issue 1/2024
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-023-04314-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Calycosin ameliorates osteoarthritis by regulating the imbalance between chondrocyte synthesis and catabolism

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Biogenic zinc selenide nanoparticles fabricated using Rosmarinus officinalis leaf extract with potential biological activity

Supplementation of papaya leaf juice has beneficial effects on glucose homeostasis in high fat/high sugar-induced obese and prediabetic adult mice

Apium extract alleviates indomethacin-induced gastric ulcers in rats via modulating the VEGF and IK-κB/NF-κB p65 signaling pathway: insights from in silico and in vivo investigations

Potential role of Citrus bergamia flower essential oil against oral pathogens

An anthocyanin-rich extract from Zea mays L. var. ceratina alleviates neuronal cell death caused by hydrogen peroxide-induced cytotoxicity in SH-SY5Y cells

Punicalagin, a pomegranate polyphenol sensitizes the activity of antibiotics against three MDR pathogens of the Enterobacteriaceae